NYSE
$1.49▲ 6.43%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $34.2MShares out 23.0M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 3d agoRegular26.10.21 23:15424B5Offering#●●●#●●●#●●●
NANOVIRICIDES, INC.Bullish
NanoViricides, Inc. (NNVC) has updated its at-the-market (ATM) offering program to allow for the sale of up to $2,374,774 in additional common stock. This amendment ensures compliance with the public primary offering limitations under General Instruction I.B.6 of Form S-3, based on the company's current public float of $43,161,651.…more
$1.49+6.43%vs prev closeView filingShare
- 10.8Regular26.10.09 00:28DEF 14AOther
NANOVIRICIDES, INC.
NanoViricides will hold its Annual Meeting of Stockholders on November 21, 2026, to vote on the election of directors and the ratification of independent auditors. As of September 21, 2026, the company had 25,439,439 shares of common stock and 918,809 shares of Series A Convertible Preferred Stock outstanding.…more
$1.49+6.43%vs prev closeView filingShare - 9.29After-hours26.09.30 05:308-KKey event
NANOVIRICIDES, INC.
NanoViricides, Inc. has extended the employment agreements for President Anil Diwan and CFO Meeta Vyas through June 30, 2027. President Diwan will receive an annual base salary of $400,000 and a grant of 10,204 shares of Series A Preferred Stock, while CFO Vyas's extension includes updated terms for health insurance cost reimbursement.…more
$1.49+6.43%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 3d agoRegular26.10.21 23:26Bullish#●●●#●●●
NanoViricides Files Prospectus For $2.375M Common Stock Offering
NanoViricides has filed a prospectus for a common stock offering valued at $2.375 million. This move may negatively impact the stock price due to potential shareholder dilution.…more
$1.49+6.43%vs prev closeDetected5m · 30m · 60m · Next dayPLUSShareBenzinga
- 5d agoPre-market26.10.20 21:47
●●●●●●●● ●●●●● ●●●●●●
NanoViricides announced that its antiviral candidate NV-387 demonstrated strong safety and tolerability in a juvenile mouse model study. The positive findings are expected to support the company's plans to initiate pediatric clinical trials for various viral diseases.…more
$1.49+6.43%vs prev closeShareBenzinga - 10.13Pre-market26.10.13 21:48
●●●●●●●● ●●●●● ●●●●●●
NanoViricides is currently conducting a Phase IIA clinical trial for its oral Ebola treatment, NV-387, in the Democratic Republic of Congo. The study aims to evaluate the safety and tolerability of the drug, with future announcements expected regarding its potential efficacy.…more
$1.49+6.43%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report